Vascular Ulcer Treatment Market Outlook

The global vascular ulcer treatment demand is expected to rise at a CAGR of 4.7%. The market revenue is likely to be valued at US$ 2,737.4 million in 2023 and exhibit a revenue growth of US$ 4,344 million by 2033. Rising cases of obesity, coupled with changing lifestyles of people, are increasing the rates of chronic illnesses, such as diabetes and vascular disease. These factors are anticipated to accelerate the vascular ulcer treatment sector.

However, lack of awareness of the benefits of the treatment and lack of skilled healthcare professionals serve as critical challenges for the market.

On the other hand, demand for compression hosiery products is expected to spur due to the high rates of recurrence after healing. This poses revenue opportunities for the vascular ulcer treatment market share.

Multi-component and two-layer compression therapy systems replacing traditional treatment options have provided clinicians the ease of bandage applications and products that deliver effective therapeutic compression. This is expected to significantly accelerate the market growth.

The preference for home care settings for the geriatric population to treat ulcers is likely to expand the market size. In addition to this, initiatives to improve the knowledge and competence about ulcer treatments for nursing staff by reliable social care service organizations are beneficial.

Trained staff offering personalized wound care products, along with the increasing number of specialty clinics with advanced facilities, is likely to expand the market at considerable growth. The rise in the hospitalization rate and increasing healthcare infrastructure is anticipated to surge the demand for vascular ulcer treatment.

Inflammation and pain in patients are attempted to be reduced by electrical stimulation and electroceuticals, which improves clinical numbers. This is further expected to accelerate the market trends.

What are the Drawbacks of Vascular Ulcer Treatment?

The vascular ulcer treatment market share is likely to obstruct due to the high costs of the products associated with the treatments. Moreover, the risk of developing new ulcers in different areas of the body is the result of prolonged surgical care, which is expected to hamper the vascular ulcer treatment industry’s size.

Lack of awareness about treatment options, as well as limited availability of healthcare professionals in underdeveloped nations, is anticipated to hinder the market growth. Furthermore, visa cancellations during the pandemic, causing a hiatus for the medical tourism sector, negatively impacted the market share.

Attributes Details
Vascular Ulcer Treatment Market CAGR (2023 to 2033) 4.7%
Vascular Ulcer Treatment Market Size (2023) US$ 2,737.4 million
Vascular Ulcer Treatment Market Size (2033) US$ 4,344 million

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Vascular Ulcer Treatment Industry Historic Outlook Vs 2023 to 2033 Forecast

The global demand for vascular ulcer treatment reached from US$ 2,341.91 million in 2018 to US$ 2,638.5 million in 2022, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.

The increasing prevalence of hypertension and peripheral vascular treatment disease are expected to surge the demand for vascular ulcer treatment. Moreover, rising awareness about innovative dressings and bio-skin treatments to provide relief to patients is likely to expand the market size.

The rising geriatric population, and the knees and hip replacement surgery implemented following previous leg surgeries, are expected to boost the market growth. Furthermore, mergers and acquisitions among market players contribute to the vascular ulcer treatment industry.

Combining different modalities for a more efficient ulcer treatment, increasing in popularity presents a key driver for the market. Likewise, the availability of different skin substitutes and technologically advanced wound care products further surges the demand.

A growing number of product launches and approvals through government initiatives are expected to increase the vascular ulcer treatment business. Research and development (R&D) activities to initiate new strategies and innovations positively impact the market.

What are the Possibilities That Expand the Vascular Ulcer Treatment Market?

New Launches:

Introduction of stockings for the testament of vascular leg ulcers and advanced compression is likely to expand the compression therapy segment. Adoption of these products and services is expected to present lucrative opportunities for the vascular ulcer treatment market.

Health Programs:

The therapeutic effects of compression hosiery products following vascular ulcer treatment are encouraging grace professionals to introduce health programs. This, along with dressings experiencing a dramatic surge in bulk orders, are likely to boost the market growth.

Clinical Evidence:

High availability of published clinical evidence concerning negative pressure wound therapy products is estimated to increase the market share. The growth of the vascular ulcer treatment sector is attributed to the increasing number of clinical trials.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Comparative View of the Market

Vascular Ulcer Treatment Market:

Attributes Vascular Ulcer Treatment Market
CAGR (2023 to 2033) 4.7%
Market Value (2023) US$ 4,344 million
Growth Factor Preference for homecare settings
Opportunity Increasing number of clinical trials
Trends Rising awareness and changing lifestyle

Vascular Access System Market:

Attributes Vascular Access System Market
CAGR (2023 to 2033) 6.6%
Market Value (2023) US$ 9,615.32 million
Growth Factor Surging number of vascular access surgeries
Opportunity Adoption of central venous catheter
Trends Cumulative aging population

Vascular Closure Devices Market:

Attributes Vascular Closure Devices Market
CAGR (2023 to 2033) 5.4%
Market Value (2023) US$ 2,529.60 million
Growth Factor Rapid expansion in healthcare
Opportunity Development of minimally invasive techniques
Trends Increase in age related cardiac ailments

Country-wise insights

Countries Market Share (2023)
United States 29.2%
Germany 5.9%
Japan 5.5%

What is the Growth Outlook for the North American Vascular Ulcer Treatment Market?

North America holds the dominant vascular ulcer treatment industry share, with a revenue of 37.1%. This is owing to the public initiatives related to diabetes and its rising cases.

Launching innovative products by key market participants significantly contributes to global market growth. Research and development activities on technologically advanced products to improve the treatment of these diseases are expected to positively impact the market.

How is the Europe Vascular Ulcer Treatment Market Growing?

With a revenue of 27.9%, Europe is the second leading vascular ulcer treatment industry. This is owing to the rapidly growing geriatric population and high medical insurer reimbursement rates in this region.

Technological developments and the growing trend to combine different modalities for more systematic ulcer treatments. Moreover, the increase in demand for active wound care products is attributed to the rising prevalence of chronic and acute wounds, especially in the United Kingdom. Due to this, the United Kingdom is expected to have a CAGR of 3.6% by 2033.

How is the Performance of the Asia-Pacific Vascular Ulcer Treatment Sector?

Countries CAGR (2023 to 2033)
India 5.6%
China 4.7%

The Asia-Pacific is expected to witness significant market growth owing to approvals and product launches. Government initiatives further expand the market size. The geriatric population increasing in number, along with the rise in healthcare infrastructure in various countries of this region, is likely to expand the market size.

In addition to this, the increasing prevalence of diabetes, as well as a significant growth in the disposable income of the middle-class population, further boosts the global demand for the treatment.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Key Companies & Start-ups Revolutionizing the Vascular Ulcer Treatment Market Space

The expansion of the vascular ulcer treatment market size is owing to the substantial growth during the forecast period, with the prevalence of chronic skin ulcers and diabetes. Hence, start-up companies have taken a keen interest in developing alternative solutions for ulcer treatments through new innovations and strategies.

  • Venari Medical - They are developers of a medical device for chronic venous disease treatment. The company offers its flagship product BioVena for treating varicose veins and venous ulcers.
  • ElastiMed - They are developing a wearable compression device to improve blood circulation in the lower extremity by mimicking rhythmic calf muscle contractions and stimulating blood flow.
  • DeVoro Medical - They are a developer of medical devices for the treatment of cardiac diseases. It has developed smart products focused on peripheral thrombectomy space with a novel flow restoration technology.

These are a few of the many start-up companies coming up with various strategies for ulcer treatments, such as peripheral thrombectomy space with a novel flow restoration technology, wearable compression devices, etc.

On the other hand, key market players strive to remain at the top with innovative plans through collaborations, and extensive research and development activities. Rising cases of chronic ulcers provide lucrative options for market players to devise strategies for the improvement and adoption of vascular ulcer treatments.

KEY MARKET PLAYERS

  • Angiodynamics

A leading provider of minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease, and oncology. The global company has over 1200 employees and currently reaches more than 50 markets via direct sales and distributors.

  • Sigvaris Group

They offer high quality and innovative offerings in medical compression therapy. Their portfolio caters to a wide range of different needs and indications. They are a reliable partner for their customers around the world, that includes pharmacies, DMEs, orthopedic and medical specialist stores, as well as medical professionals and hospitals.

  • Medtronic

They are significantly growing in biomedical engineering, where they display maximum strength and ability. They provide ground-breaking healthcare technology solutions for the most complex and challenging conditions.

  • 3M

They have a dedication to produce products that provide genuine solutions to real world problems, or products that simply speed up processes to make tasks and surgeries easier. From personal protective equipment to adhesives and insulation-displacement connectors.

Recent Developments:

  • Woxheal, a New Chemical Entity (NCE), was introduced in India on September 28, 2020 by Centaur Pharmaceuticals, a fully integrated pharmaceutical business with knowledge of the whole pharmaceutical value chain.
  • In October 2019, PolarityTE Inc. announced findings from an open-label, single-arm pilot study, which examined the impact of SkinTE, a novel human cellular and tissue-based product derived from a patient’s own skin, in closing leg ulcers following failure of conventional treatments.
  • In October 2019, 3M completed the acquisition of Acelity Inc. and its KCI subsidiaries worldwide with an aim to expand its product offerings in advanced and surgical wound care.
  • In June 2019, Milliken & Company acquired Andover Healthcare, aiming to provide innovative and comprehensive solutions for patient care.
  • In February 2019, AxioBiosolutions launched MaxioCel, the next generation chitosan-based advanced wound care dressing for the treatment of chronic wounds, such as diabetic foot ulcer, venous leg ulcers, and other complex wounds.

Key Players

  • Angiodynamics
  • Sigvaris Global
  • Medi GmbH & Co. KG
  • Activa Healthcare
  • 3M
  • Medtronic
  • B. Braun Melsungen AG
  • Bristol Myers Squibb Co
  • Sanofi
  • Bayer AG
  • Pfizer Inc
  • Novo Nordisk A/S
  • Cadila Pharmaceuticals Ltd.
  • Cardinal Health
  • Paul Hartmann AG
  • Coloplast Corporation
  • KCI Licensing Inc.
  • Smith & Nephew plc
  • Integra LifeSciences Corporation
  • Mölnlycke Health Care AB

Key Segments

By Type:

  • Arterial Ulcers
  • Neurotrophic Ulcers
  • Venous Ulcers
  • Diabetic Ulcers

By Treatment:

  • Compression
  • Gradual Compression
  • Intermittent Pneumatic Compression
  • Drugs
  • Antibiotics
  • Pentoxifylline
  • Topical Steroids
  • Aspirin
  • Dressings
  • Surgical Therapy
  • Skin Grafting

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies & E-Commerce
  • Drugstores

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

Frequently Asked Questions

How is the Vascular Ulcer Treatment Market Evolving?

The market is expected to rise at a CAGR of 4.7% from 2023 to 2033.

What are the Current Trends in the Vascular Ulcer Treatment Market?

Telemedicine for remote patient monitoring is the key trend in the market.

Which Segment Leads in the Vascular Ulcer Treatment Market?

Advanced wound care products segment is the current market leader.

What Insights can you Provide About the Vascular Ulcer Treatment Market?

Growing elderly population and incidence of vascular and diabetic illnesses driving the market.

What Regions are Prominent in the Vascular Ulcer Treatment Market?

North America, Europe, and Asia Pacific are prominent regions in the market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Arterial Ulcers

        5.3.2. Neurotrophic Ulcers

        5.3.3. Venous Ulcers

        5.3.4. Diabetic Ulcers

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        6.3.1. Compression

        6.3.2. Gradual Compression

        6.3.3. Intermittent Pneumatic Compression

        6.3.4. Drugs

        6.3.5. Antibiotics

        6.3.6. Pentoxifylline

        6.3.7. Topical Steroids

        6.3.8. Aspirin

        6.3.9. Dressings

        6.3.10. Surgical Therapy

        6.3.11. Skin Grafting

    6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies & E-Commerce

        7.3.4. Drugstores

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Treatment

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Treatment

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Treatment

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Treatment

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Type

        11.2.3. By Treatment

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Treatment

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Type

        12.2.3. By Treatment

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Treatment

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Type

        13.2.3. By Treatment

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Treatment

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Type

        14.2.3. By Treatment

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Treatment

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Type

        15.2.3. By Treatment

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Type

        15.3.3. By Treatment

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Type

            16.1.2.2. By Treatment

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Type

            16.2.2.2. By Treatment

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Type

            16.3.2.2. By Treatment

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Type

            16.4.2.2. By Treatment

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Type

            16.5.2.2. By Treatment

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Type

            16.6.2.2. By Treatment

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Type

            16.7.2.2. By Treatment

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Type

            16.8.2.2. By Treatment

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Type

            16.9.2.2. By Treatment

            16.9.2.3. By Distribution Channel

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Type

            16.10.2.2. By Treatment

            16.10.2.3. By Distribution Channel

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Type

            16.11.2.2. By Treatment

            16.11.2.3. By Distribution Channel

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Type

            16.12.2.2. By Treatment

            16.12.2.3. By Distribution Channel

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Type

            16.13.2.2. By Treatment

            16.13.2.3. By Distribution Channel

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Type

            16.14.2.2. By Treatment

            16.14.2.3. By Distribution Channel

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Type

            16.15.2.2. By Treatment

            16.15.2.3. By Distribution Channel

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Type

            16.16.2.2. By Treatment

            16.16.2.3. By Distribution Channel

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Type

            16.17.2.2. By Treatment

            16.17.2.3. By Distribution Channel

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Type

            16.18.2.2. By Treatment

            16.18.2.3. By Distribution Channel

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Type

            16.19.2.2. By Treatment

            16.19.2.3. By Distribution Channel

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Type

            16.20.2.2. By Treatment

            16.20.2.3. By Distribution Channel

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Type

            16.21.2.2. By Treatment

            16.21.2.3. By Distribution Channel

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Type

            16.22.2.2. By Treatment

            16.22.2.3. By Distribution Channel

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Type

            16.23.2.2. By Treatment

            16.23.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Type

        17.3.3. By Treatment

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Angiodynamics

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Sigvaris Global

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Medi GmbH & Co. KG

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Activa Healthcare

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. 3M

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Medtronic

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. B. Braun Melsungen AG

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Bristol Myers Squibb Co

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Sanofi

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Bayer AG

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Pfizer Inc

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. Novo Nordisk A/S

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

        18.1.13. Cadila Pharmaceuticals Ltd.

            18.1.13.1. Overview

            18.1.13.2. Product Portfolio

            18.1.13.3. Profitability by Market Segments

            18.1.13.4. Sales Footprint

            18.1.13.5. Strategy Overview

                18.1.13.5.1. Marketing Strategy

        18.1.14. Cardinal Health

            18.1.14.1. Overview

            18.1.14.2. Product Portfolio

            18.1.14.3. Profitability by Market Segments

            18.1.14.4. Sales Footprint

            18.1.14.5. Strategy Overview

                18.1.14.5.1. Marketing Strategy

        18.1.15. Paul Hartmann AG

            18.1.15.1. Overview

            18.1.15.2. Product Portfolio

            18.1.15.3. Profitability by Market Segments

            18.1.15.4. Sales Footprint

            18.1.15.5. Strategy Overview

                18.1.15.5.1. Marketing Strategy

        18.1.16. Coloplast Corporation

            18.1.16.1. Overview

            18.1.16.2. Product Portfolio

            18.1.16.3. Profitability by Market Segments

            18.1.16.4. Sales Footprint

            18.1.16.5. Strategy Overview

                18.1.16.5.1. Marketing Strategy

        18.1.17. KCI Licensing Inc.

            18.1.17.1. Overview

            18.1.17.2. Product Portfolio

            18.1.17.3. Profitability by Market Segments

            18.1.17.4. Sales Footprint

            18.1.17.5. Strategy Overview

                18.1.17.5.1. Marketing Strategy

        18.1.18. Smith & Nephew plc

            18.1.18.1. Overview

            18.1.18.2. Product Portfolio

            18.1.18.3. Profitability by Market Segments

            18.1.18.4. Sales Footprint

            18.1.18.5. Strategy Overview

                18.1.18.5.1. Marketing Strategy

        18.1.19. Integra LifeSciences Corporation

            18.1.19.1. Overview

            18.1.19.2. Product Portfolio

            18.1.19.3. Profitability by Market Segments

            18.1.19.4. Sales Footprint

            18.1.19.5. Strategy Overview

                18.1.19.5.1. Marketing Strategy

        18.1.20. Mölnlycke Health Care AB

            18.1.20.1. Overview

            18.1.20.2. Product Portfolio

            18.1.20.3. Profitability by Market Segments

            18.1.20.4. Sales Footprint

            18.1.20.5. Strategy Overview

                18.1.20.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Decubitus Ulcer Treatment Products Market

April 2016

REP-GB-1438

August 2023

324 pages

Healthcare

Corneal Ulcer Treatment Market

February 2020

REP-GB-6953

June 2022

244 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Vascular Ulcer Treatment Market